AIM
To study clinical effectiveness and tolerance of diovan, a new angiotensin-II antagonist, in patients with mild and moderate blood hypertension (BH).


MATERIALS AND METHODS
The trial included 20 patients (13 males and 7 females) aged 35-60 years with mild and moderate BH. All the patients received diovan (valsartan) for 8 weeks in a dose 80 mg/day. If the hypotensive effect was inadequate, the dose was increased to 160 mg/day.


RESULTS
2-week treatment with diovan brought a significant fall of both systolic and diastolic blood pressure. In 8 weeks the hypotensive effect enhanced. Lowering of diastolic BP to 90 mm Hg or at least by 10% was achieved in 90% of the patients. Tolerance was good, unfavorable metabolic shifts were absent.


CONCLUSION
Diovan proved to be effective and safe in therapy of patients with mild and moderate BH.

Diovan is an effective and safe treatment for mild and moderate blood hypertension, lowering blood pressure in 90% of patients and exhibiting good tolerance without unfavorable metabolic shifts.

[Diovan efficacy and tolerance in mild and moderate hypertension].